Our raise is now in its final stage and closes at 10 pm tonight - Thursday the 11th of December. If you have been following our progress, this is a good moment to take a closer look at what BioAnalytics is building. Sleep apnoea affects around 8 percent of adults, yet about 40 percent of people cannot tolerate existing therapies. Our device addresses this unmet need with a simpler, patented, low-cost approach supported by published evidence, regulatory approval for the core therapeutic device, and a clear pathway to an independent 20–30 patient clinical trial. We have also added electronics and data capability so the device becomes part of the digital health ecosystem, providing vital patient feedback and enabling remote clinical monitoring. We are focused on creating a high-quality medtech asset backed by strong intellectual property, long-term users of the device, and a well-defined commercialisation pathway. Further information, including our trial data and detailed strategy, is available on the offer page. Thank you to everyone who has supported us so far.

In under 2 minutes: an expert explains BioAnalytics’ new sleep apnoea treatment Our window to invest closes today - please join us